Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.

R, Cappato; FE, Marchlinski; SH, Hohnloser; GV, Naccarelli; J, Xiang; DJ, Wilber; CS, Ma; S, Hess; DS, Wells; G, Juang; J, Vijgen; BJ, Hügl; R, Balasubramaniam; Chillou C, De; DW, Davies; LE, Fields; A, Natale

doi:10.1093/eurheartj/ehv177

Public

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.

Shared by NobleBlocks on May 14, 2015 • 12:00 AM UTC

Authors:

Cappato R

Marchlinski FE

Hohnloser SH

Abstract

Aims VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation (CA).Methods and results Trial size was administratively set at 250, the protocol-specified ta...

Subject

Atrial fibrillation

Catheter ablation

Thromboembolism

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!